Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease

NCT05507892 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05507892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 10, 2022
Completion date
December 15, 2026
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease, type 2 diabetes